Inhibikase Therapeutics Earning Date (IKT)

USA |NASDAQ |USD

IKT Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
May 16, 2022 Mar 2022 $0.00 $-0.18 $-0.22
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
May 16, 2022 Mar 2022 $0.00 $328.46K $1.41M

Inhibikase Therapeutics's next earnings date is Monday, May 16, 2022 for the fiscal quarter ending Mar 2022.

IKT Earnings Date & History Chart

IKT Earnings & Revenue Forecast

IKT Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 1 $-0.17 $-0.17 $-0.17
Mar 2022 0 $0.00 $0.00 $0.00
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 1 $-0.78 $-0.78 $-0.78
Dec 2022 1 $-0.61 $-0.61 $-0.61

IKT Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $-0.15 $-0.15 $-0.16
Mar 2022 0 / 0 $0.00 $0.00 $0.00
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 1 $-0.62 $-0.62 $-0.68
Dec 2022 0 / 1 $-0.67 $-0.67 $-0.69

IKT Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 1 $300.00K $300.00K $300.00K
Mar 2022 0 $0.00 $0.00 $0.00
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 1 $3.40M $3.40M $3.40M
Dec 2022 1 $2.70M $2.70M $2.70M

IKT Earnings Date & Revenue History

IKT Earnings History

|
Show More
Show More

IKT Revenue History

|
Show More
Show More

Inhibikase Therapeutics Next Earnings Date & Report

IKT Next Earnings Date & Report Preview: Mar 2022 (FQ)

IKT's next earnings date is Monday, May 16, 2022 for the fiscal quarter ending Mar 31, 2022.

According to analysts, the average EPS estimation for Inhibikase Therapeutics's next quarterly earnings is $0.00, with a low EPS estimation of $0.00, and a high estimation of $0.00.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $0.00, the last 2 month trend is $0.00, and the 3 month trend is $0.00.

Based on analysts, the average revenue estimation is $0.00, with a low revenue estimation of $0.00, and a high estimation of $0.00.

Inhibikase Therapeutics Previous Earnings Dates & Reports

IKT Previous Earnings Date & Report Recap: Sep 2021 (FQ)

Inhibikase Therapeutics's previous earnings date was Nov 15, 2021 for its fiscal quarter ended Sep 30, 2021.

IKT's earnings per share (EPS) was $-0.18, missing the consensus analysts forecast of $-0.14 by -28.57%.

The EPS was higher than the previous fiscal quarter (Jun 2021) by -18.18%, and lower than the same period a year before (Sep 2020) by 23.46%.

Revenues were $328.46K, better than the forecast of $328.00K by 0.14%, down by -75.90% from the previous quarter , and up by 771.71% from the same period last year.

The company reported a net income of $-4.47M.

Free cash flow for the quarter was $-2.02M , compared to $-4.25M last quarter and $75.52K a year before.

IKT ended the quarter with $248.91K in total debt, an increase of 0.00% compared to the previous quarter.

IKT Previous Earnings Date & Report Recap: Dec 2020 (FY)

Inhibikase Therapeutics's previous annual earnings date was Mar 31, 2021 for its fiscal year ended Dec 31, 2020.

IKT's earnings per share (EPS) was $-0.54.

Revenues were $698.47K, down by -37.79% from previous year's revenue.

The company reported a net income of $-2.85M.

Inhibikase Therapeutics reported a free cash flow of $-1.13M for its fiscal year, compared to $-338.29K a year ago.

The company ended the fiscal year with $42.53 in total debt, a decrease of -99.99% compared to the previous year.